Compare Cardinal Health Inc (CAH) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Hyatt Hotels Corporation — how do they compare? Cardinal Health Inc trades at $228.22 (market cap $53.89B), while Hyatt Hotels Corporation trades at $192.74 (market cap $17.86B). The key difference: Cardinal Health Inc is far larger — about 3× Hyatt Hotels Corporation's market cap, and Cardinal Health Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| CAH | H | |
|---|---|---|
Market Cap | $53.89B | $17.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $239.71 | $202.09 |
52-Week Low | $146.04 | $135.01 |
Enterprise Value | $58.87B | $21.71B |
Dividend Yield | 0.89% | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Hyatt Hotels (H) trades at $184.72, down 3.36% in the last session, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q1 2026 EPS of $0.63, beating expectations, but faces profitability challenges with negative net income margins and ROE. Recent developments include expansion announcements and strategic investor presentations, while analyst consensus remains cautiously optimistic with a $198.20 price target.
Hyatt presents a growth opportunity through hotel expansion and premium positioning, but investors face risks from inconsistent profitability, rising debt levels, and economic sensitivity. The stock's valuation appears stretched with a P/E of 31.36, requiring strong execution on revenue growth and margin improvement to justify current levels amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
